Optimized antiretroviral therapy during allogeneic hematopoietic stem cell transplantation in HIV-1-infected individuals
Johns Hopkins Kimmel Cancer Center in Baltimore
To determine the fraction of patients who maintain antiretroviral therapy (ART), through day 60 of allogeneic hematopoietic stem cell transplant(alloHSCT).
HIV-1-infected individuals who plan to undergo a myeloablative or non- myeloablative bone marrow transplant
This is a one arm single institution study. HIV-1 infected patients undergoing alloHSCT are eligible. A multidisciplinary team will select an optimal ART regimen and every effort will be made to maintain this oral ART regimen through day 60 day post-alloHSCT. In addition, the subcutaneous antiretroviral, enfuvirtide, will be added during any periods when oral medications are unlikely to be tolerated due to nausea (e.g. during administration of high dose cyclophosphamide) or cannot be tolerated for other reasons (e.g. mucositis).
05/25/2016 05:03 AM